Medicare AdvantageCoverageMedium impact
20-580sum Summary Update: Stay Up to Date with Medication Trend Updates and Formulary Changes - 3rd Quarter
Health Net·CA · Family Medicine, Internal Medicine, Endocrinology +2 more·Pharmacy
We identified it
Jun 20, 2026
Summary
Health Net has withdrawn weight-loss drugs Belviq and Belviq XR from the market due to increased cancer risk, updated their zero copayment program for Medicare Advantage members, and made changes to their commercial, Medi-Cal, and Medicare Part D formularies for Q3 2020. Providers must stop prescribing these withdrawn medications and inform current patients to discontinue use.
Action Required
Immediately: Stop prescribing and dispensing Belviq and Belviq XR (lorcaserin) to all patients. Providers must contact current patients taking lorcaserin to inform them of cancer risks and instruct them to stop taking the medication. Discuss alternative weight-loss treatments with affected patients. Review updated formulary changes available in complete provider update 20-580 on Health Net provider portal.